NASDAQ$MIST
Milestone Pharmaceuticals Inc · Q3 2024 earnings
Q3 2024 earnings · · Investor relations
Briefing
Milestone Pharmaceuticals reported financial results for the third quarter ended September 30, 2024.
Milestone Pharmaceuticals is preparing for potential FDA approval of CARDAMYST (etripamil) nasal spray for the management of PSVT and is encouraged by clinician interest in the etripamil Phase 3 study in AFib-RVR.
- NDA for CARDAMYST™ in PSVT under review by FDA with a PDUFA date of March 27, 2025.
- Primary focus is preparing for potential FDA approval of CARDAMYST (etripamil) nasal spray for PSVT management.
- Clinician interest is high for the etripamil Phase 3 study in AFib-RVR, planned to commence in the first half of 2025.
- Etripamil is a novel calcium channel blocker nasal spray under clinical development for PSVT and AFib-RVR.
Headline financials
Revenue & EPS history
Milestone Pharmaceuticals · Revenue · Quarterly
$0
Forward guidance
Milestone Pharmaceuticals is focused on the potential FDA approval and commercial launch of CARDAMYST for PSVT, while also planning for a Phase 3 study in AFib-RVR.
Tailwinds
- Potential FDA approval of CARDAMYST for PSVT.
- Commercial launch of etripamil for PSVT.
- Phase 3 study in AFib-RVR commencing in the first half of 2025.
- CARDAMYST has the potential to improve how PSVT is managed.
- CARDAMYST positions Milestone to deliver meaningful value to patients, providers, and payors.
Headwinds
- Uncertainties related to the timing of initiation, enrollment, completion, evaluation and results of clinical trials.
- Risks related to the complexity inherent in cleaning, verifying and analyzing trial data.
- Whether the clinical trials will validate the safety and efficacy of etripamil for PSVT or other indications.
- General economic, political, and market conditions.
- Risks related the sufficiency of Milestone’s capital resources and its ability to raise additional capital in the current economic climate.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 19 quarterly earnings reports · overlaid with Q3 2024
+1.7%
Avg return
Earnings day
-0.2%
Avg return
5 days after
+2.2%
Avg return
30 days after
64%
18 / 28 earnings
Positive
+24.1%
Q3 2021
Best reaction
-23.0%
Q3 2023
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | -9.5% | -23.2% | — | |
| Q4 2026 | -20.0% | -26.5% | +23.5% | |
| Q3 2025 | +1.0% | +21.5% | +26.2% | |
| Q2 2025 | +7.1% | +9.7% | +23.2% | |
| Q1 2025 | -1.7% | +8.4% | +38.7% | |
| Q4 2024 | +7.9% | -53.7% | -38.9% | |
| Q3 2024 | -5.2% | -12.4% | -4.1% | |
| Q1 2024 | +1.2% | +2.4% | -16.5% | |
| Q4 2023 | +16.0% | +20.7% | +9.3% | |
| Q3 2023 | -23.0% | -24.4% | -13.7% | |
| Q2 2023 | +1.6% | +2.6% | -7.1% | |
| Q1 2023 | +12.8% | +0.5% | +1.3% | |
| Q4 2022 | -4.0% | -0.3% | -9.0% | |
| Q3 2022 | +13.0% | +7.1% | -0.7% | |
| Q2 2022 | +3.6% | +5.3% | +29.2% | |
| Q1 2022 | -2.5% | +1.6% | +1.6% | |
| Q4 2021 | +12.4% | +17.5% | +22.0% | |
| Q3 2021 | +24.1% | +13.9% | +4.5% | |
| Q2 2021 | +0.2% | +2.1% | +7.1% | |
| Q1 2021 | +0.5% | +1.3% | +6.1% | |
| Q4 2020 | -6.6% | -2.4% | -4.0% | |
| Q3 2020 | +6.1% | +6.0% | +19.8% | |
| Q2 2020 | -1.8% | +0.3% | -12.2% | |
| Q1 2020 | +0.3% | +4.8% | +29.5% | |
| Q4 2019 | +7.4% | +8.7% | -90.4% | |
| Q3 2019 | -4.2% | -1.2% | -7.2% | |
| Q2 2019 | +7.8% | +9.9% | +38.1% | |
| Q1 2019 | +3.4% | -4.5% | -16.2% | |
| Q4 2018 | — | — | — | |
| Q3 2018 | — | — | — | |
| Q2 2018 | — | — | — | |
| Q1 2018 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro